Positron emission tomography (PET) integrated with computed tomography (CT) (PET/CT) provides both metabolic and morphologic information, and becomes the most sensitive and specific imaging armamentarium in patients with non-Hodgkin lymphoma (NHL) and HL. This multimodality is being routinely used in staging, response assessment, and end-of-treatment evaluation for most lymphoma subtypes with convincing data. However, there are still controversial issues in the clinical management of patients with lymphoma. This comprehensive review addresses the latest information regarding the appropriate application of Fluorine 18 fluorodeoxyglucose ((18)F-FDG) PET/CT, discusses the current dilemma in the prognostic value of interim PET/CT, and tries to clarify questions existing in PET/CT-navigated application.
Keywords: Positron emission tomography (PET); computed tomography (CT); lymphoma.